STOCK TITAN

Relmada Therapeutics (RLMD) gains 7.0% shareholder position from Squadron funds

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. has a significant shareholder group led by investment entities affiliated with Squadron Capital Management LLC. Squadron Master Fund LP, Squadron Capital Management LLC, and individuals Matthew Sesterhenn and William Blank each report beneficial ownership of 7,350,000 shares of common stock of Relmada Therapeutics.

This position represents 7.0% of the common stock class, based on 104,890,223 shares outstanding as of May 7, 2026. The reporting persons have no sole voting or dispositive power over these shares but report shared voting and shared dispositive power over 7,350,000 shares. The filing states that Squadron Capital Management LLC and Messrs. Sesterhenn and Blank may be deemed beneficial owners through their roles with the funds, while expressly disclaiming beneficial ownership under Rule 13d-4. The funds have the right to receive dividends and sale proceeds from the reported shares.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 7,350,000 shares Reported by each of Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn and William Blank
Percent of class 7.0% Ownership percentage of Relmada common stock for each reporting person
Shares outstanding 104,890,223 shares Relmada common stock outstanding as of May 7, 2026, used to calculate ownership percentage
Shared voting power 7,350,000 shares Shares over which reporting persons have shared power to vote or direct the vote
Shared dispositive power 7,350,000 shares Shares over which reporting persons have shared power to dispose or direct disposition
As-of date for outstanding shares May 7, 2026 Date of Relmada’s outstanding share count referenced from its Form 10-Q
beneficial owner financial
"may be deemed to be the beneficial owner of all shares of Common Stock"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
shared voting power financial
"Shared Voting Power 7,350,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 7,350,000.00"
Investment Advisers Act of 1940 regulatory
"an investment adviser that is registered under the Investment Advisers Act of 1940"
A U.S. federal law that sets rules for people and firms who give investment advice, requiring them to register with regulators, be honest about conflicts, keep records, and follow basic standards of care. It matters to investors because those rules act like licensing and consumer protections — similar to having safety standards for a mechanic — helping ensure advisers act in clients’ financial interests and reducing the risk of fraud or misuse of funds.
Rule 13d-4 regulatory
"Pursuant to Rule 13d-4 , as amended, Squadron Capital Management, LLC"

FAQ

What percentage of Relmada Therapeutics (RLMD) does Squadron Master Fund report owning?

Squadron Master Fund LP and related reporting persons each report 7.0% beneficial ownership of Relmada Therapeutics common stock. This is based on 104,890,223 shares outstanding as of May 7, 2026, as referenced in the Schedule 13G/A.

Do Squadron Capital Management and its partners claim full beneficial ownership of RLMD shares?

They state they may be deemed beneficial owners through advisory and control roles over the funds, but they expressly disclaim beneficial ownership of the securities under Rule 13d-4, limiting the interpretation of their reported interest.

Who has rights to dividends and sale proceeds on the reported RLMD shares?

The filing explains that the funds advised by Squadron Capital Management have the right to receive dividends and proceeds from any sale of the 7,350,000 Relmada Therapeutics shares covered by the Schedule 13G/A.

What type of power do Squadron entities have over their Relmada Therapeutics (RLMD) shares?

The reporting persons disclose 0 shares with sole voting or dispositive power and 7,350,000 shares with shared voting and shared dispositive power. This means decisions over these shares are exercised jointly, not individually.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





75955J402

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Squadron Master Fund LP
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner, Squadron Partners LLC, its General Partner
Date:08/14/2026
Squadron Capital Management LLC
Signature:/s/ Matthew Sesterhenn
Name/Title:Partner
Date:08/14/2026
Matthew Sesterhenn
Signature:/s/ Matthew Sesterhenn
Name/Title:Matthew Sesterhenn
Date:08/14/2026
William Blank
Signature:/s/ William Blank
Name/Title:William Blank
Date:08/14/2026